Symptoms, change in peak expiratory flow rate (PEFR) and change in reliever inhaler use in fluticasone (F) and placebo (P) during study. Figures a) and b) show the proportion of patients in each drug group recording cough and wheeze on their diary card. Reporting of cough was significant between groups in first 3 months only: OR 1.95 (CI 1.16 to 3.29) P < 0.05. Wheeze was significant between groups for whole year: OR 1.83 (CI 1.06 to 3.18) P < 0.05. Figures c) and d) show mean change from baseline for PEFR and reliever inhaler use. Baseline for PEFR and reliever inhaler use was calculated from the mean value from day -8 to -1 prior to randomisation. PEFR was not significant between groups at 12 months: Mean difference 7.86 l/min (CI -1.45 to 17.17) P > 0.05. Reliever inhaler was significant in first month only: Mean difference 0.53 inh/day (CI 0.06 to 1.00) P < 0.05. (inh/day = inhalations of reliever inhaler per day).